ARCT logo

ARCT
Arcturus Therapeutics Holdings Inc

5,490
Mkt Cap
$190.15M
Volume
428,388.00
52W High
$24.17
52W Low
$5.85
PE Ratio
-2.38
ARCT Fundamentals
Price
$6.82
Prev Close
$6.69
Open
$6.70
50D MA
$7.93
Beta
1.71
Avg. Volume
380,661.26
EPS (Annual)
-$2.40
P/B
0.99
Rev/Employee
$605,594.59
$38.03
Loading...
Loading...
News
all
press releases
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +16.91% and -73.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·13d ago
News Placeholder
More News
News Placeholder
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...
Business Wire·13d ago
News Placeholder
Arcturus Therapeutics (ARCT) Projected to Post Earnings on Thursday
Arcturus Therapeutics (NASDAQ:ARCT) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...
MarketBeat·20d ago
News Placeholder
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +9.70% and +1.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Shares Cross Below 200 Day Moving Average - Time to Sell?
Arcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below 200-Day Moving Average - What's Next...
MarketBeat·23d ago
News Placeholder
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...
Business Wire·23d ago
News Placeholder
Diversify Advisory Services LLC Sells 115,500 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
Diversify Advisory Services LLC reduced its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 88.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,00...
MarketBeat·1mo ago
News Placeholder
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of "Moderate Buy" from Brokerages
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the thirteen brokerages that are currently covering the firm...
MarketBeat·1mo ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below Two Hundred Day Moving Average - What's Next?
Arcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below Two Hundred Day Moving Average - What's Next...
MarketBeat·1mo ago
News Placeholder
Hennion & Walsh Asset Management Inc. Purchases 161,910 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
Hennion & Walsh Asset Management Inc. grew its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 206.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 240,303 shares of the biotechnology company's stock after buying an additional 16...
MarketBeat·2mo ago
<
1
2
...
>

Latest ARCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.